Commission Implementing Decision (EU) 2022/1496 of 8 September 2022 postponing the expiry date of the approval of tebuconazole for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
Draft Joint Committee Decision (JCD) under consideration by the EU (EEAS) and the EFTA States (Iceland, Liechtenstein and Norway) Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XV Dangerous Substances
Legal documents
Commission Implementing Decision (EU) 2022/1496 of 8 September 2022 postponing the expiry date of the approval of tebuconazole for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Durchführungsbeschluss (EU) 2022/1496 der Kommission vom 8. September 2022 zur Verschiebung des Ablaufdatums der Genehmigung von Tebuconazol zur Verwendung in Biozidprodukten der Produktart 8 gemäß der Verordnung (EU) Nr. 528/2012 des Europäischen Parlaments und des Rates
History
15.02.2023
Draft Joint Commitee Decision (JCD) incorporating the act into the EEA Agreement sent to Commission
08.09.2022
Adoption date in the EU
29.09.2022
Compliance date in the EU
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.